Eiger BioPharmaceuticals, Inc.
EIGR
Rang in aandelen
#36453
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Aandeelprijs
$1.73
Laatst gesynchroniseerd: 2025-06-17
Marktkapitalisatie
$2.55M
Verandering (1 dag)
-0.29%
Verandering (1 jaar)
-79.71%
Land
US
Handel Eiger BioPharmaceuticals, Inc. (EIGR)
Categorie
Healthcare
P/S-ratio voor Eiger BioPharmaceuticals, Inc. (EIGR)
P/S-ratio op October 2026 TTM: 0.80
Volgens de meest recente financiële rapporten en aandelenkoers van Eiger BioPharmaceuticals, Inc. is de huidige P/S-ratio (TTM) 0.80. Eind 2022 had het bedrijf een P/S-ratio van 3.64.
P/S-ratiohistoriek voor Eiger BioPharmaceuticals, Inc. van 2016 tot 2026
P/S-ratio aan het einde van elk jaar
| Jaar | P/S-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 0.80 | 20.91% |
| 2023 | 0.66 | -81.89% |
| 2022 | 3.64 | -74.89% |
| 2021 | 14.51 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
P/S-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/S-ratio | Verschil in P/S-ratio | Land |
|---|---|---|---|
| 10.02 | 1,155.90% |
US
|
|
| 40.55 | 4,981.55% |
US
|
|
| 3.96 | 396.38% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 1,171.47% |
NL
|
